301 related articles for article (PubMed ID: 22318523)
1. Targeted therapy for biliary tract cancers.
Faris JE; Zhu AX
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):326-36. PubMed ID: 22318523
[TBL] [Abstract][Full Text] [Related]
2. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
El-Khoueiry AB; Rankin C; Siegel AB; Iqbal S; Gong IY; Micetich KC; Kayaleh OR; Lenz HJ; Blanke CD
Br J Cancer; 2014 Feb; 110(4):882-7. PubMed ID: 24423918
[TBL] [Abstract][Full Text] [Related]
3. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
5. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the systemic treatment of metastatic papillary renal cancer.
Chowdhury S; Choueiri TK
Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
[TBL] [Abstract][Full Text] [Related]
7. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
[TBL] [Abstract][Full Text] [Related]
8. Targeting EGFR in bilio-pancreatic and liver carcinoma.
Fratto ME; Santini D; Vincenzi B; Silvestris N; Azzariti A; Tommasi S; Zoccoli A; Galluzzo S; Maiello E; Colucci G; Tonini G
Front Biosci (Schol Ed); 2011 Jan; 3(1):16-22. PubMed ID: 21196353
[TBL] [Abstract][Full Text] [Related]
9. [Targeted therapies: sequential and combined treatments].
Gross-Goupil M; Escudier B
Bull Cancer; 2010; 97():65-71. PubMed ID: 20418205
[TBL] [Abstract][Full Text] [Related]
10. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
11. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Zhu AX
Cancer; 2008 Jan; 112(2):250-9. PubMed ID: 18041064
[TBL] [Abstract][Full Text] [Related]
12. [EGFR/HER1: a target life].
Viel E; Curtit E; Mansi L; Vignot S
Bull Cancer; 2012 Feb; 99(2):181-9. PubMed ID: 21684835
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy for Biliary Tract Cancer].
Woo SM
Korean J Gastroenterol; 2017 Mar; 69(3):172-176. PubMed ID: 28329919
[TBL] [Abstract][Full Text] [Related]
14. New treatment approaches in metastatic renal cell carcinoma.
Mancuso A; Sternberg CN
Curr Opin Urol; 2006 Sep; 16(5):337-41. PubMed ID: 16905978
[TBL] [Abstract][Full Text] [Related]
15. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
16. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
17. Novel agents for the treatment of advanced kidney cancer.
Cooney MM; Remick SC; Vogelzang NJ
Clin Adv Hematol Oncol; 2004 Oct; 2(10):664-70. PubMed ID: 16163253
[TBL] [Abstract][Full Text] [Related]
18. [Indications and current development of new targeted therapies in pediatric oncology].
Leblond P; Geoerger B
Bull Cancer; 2011 May; 98(5):527-39. PubMed ID: 21596652
[TBL] [Abstract][Full Text] [Related]
19. BINGO: targeted therapy for advanced biliary-tract cancer.
Valle JW
Lancet Oncol; 2014 Jul; 15(8):778-80. PubMed ID: 24852117
[No Abstract] [Full Text] [Related]
20. [Effect of angiogenesis inhibitors on renal cell carcinoma].
Bodrogi I
Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]